OBJECTIVE: Mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A) is a lysosomal storage disorder caused by deficiency of the enzyme sulfamidase. Information on the natural course of MPS IIIA is scarce, but is much needed in view of emerging therapies. METHODS: Clinical history and molecular defects of all 110 MPS IIIA patients identified by enzymatic studies in the Netherlands were collected and included in this study. RESULTS: First clinical signs, mainly consisting of delayed speech development and behavioral problems, were noted between the ages of 1 and 6 years. Other symptoms included sleeping and hearing problems, recurrent upper airway infections, diarrhea, and epilepsy. The clinical course varied remarkably and could be correlated with the molecular defects. The frequent pathogenic mutations p.R245H, p.Q380R, p.S66W, and c.1080delC were associated with the classical severe phenotype. Patients compound heterozygous for the p.S298P mutation in combination with 1 of the mutations associated with the classical severe phenotype had a significantly longer preservation of psychomotor functions and a longer survival. Two patients homozygous for the p.S298P mutation, and 4 patients from 3 families heterozygous for 3 missense variants not reported previously (p.T421R, p.P180L, and p.L12Q), showed a remarkably attenuated phenotype. INTERPRETATION: We report the natural history and mutational analysis in a large unbiased cohort of MPS IIIA patients. We demonstrate that the clinical spectrum of MPS IIIA is much broader than previously reported. A significant genotype-phenotype correlation was established in this cohort.
OBJECTIVE:Mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A) is a lysosomal storage disorder caused by deficiency of the enzyme sulfamidase. Information on the natural course of MPS IIIA is scarce, but is much needed in view of emerging therapies. METHODS: Clinical history and molecular defects of all 110 MPS IIIApatients identified by enzymatic studies in the Netherlands were collected and included in this study. RESULTS: First clinical signs, mainly consisting of delayed speech development and behavioral problems, were noted between the ages of 1 and 6 years. Other symptoms included sleeping and hearing problems, recurrent upper airway infections, diarrhea, and epilepsy. The clinical course varied remarkably and could be correlated with the molecular defects. The frequent pathogenic mutations p.R245H, p.Q380R, p.S66W, and c.1080delC were associated with the classical severe phenotype. Patients compound heterozygous for the p.S298P mutation in combination with 1 of the mutations associated with the classical severe phenotype had a significantly longer preservation of psychomotor functions and a longer survival. Two patients homozygous for the p.S298P mutation, and 4 patients from 3 families heterozygous for 3 missense variants not reported previously (p.T421R, p.P180L, and p.L12Q), showed a remarkably attenuated phenotype. INTERPRETATION: We report the natural history and mutational analysis in a large unbiased cohort of MPS IIIApatients. We demonstrate that the clinical spectrum of MPS IIIA is much broader than previously reported. A significant genotype-phenotype correlation was established in this cohort.
Authors: Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley Journal: J Pediatr Date: 2016-01-16 Impact factor: 4.406
Authors: J de Ruijter; L Broere; M F Mulder; A T van der Ploeg; M E Rubio-Gozalbo; S B Wortmann; G Visser; F A Wijburg Journal: J Inherit Metab Dis Date: 2013-10-31 Impact factor: 4.982
Authors: Fedah E Mohamed; Mohammad Al Sorkhy; Mohammad A Ghattas; Nuha Al-Zaabi; Aisha Al-Shamsi; Taleb M Almansoori; Lihadh Al-Gazali; Osama Y Al-Dirbashi; Fatma Al-Jasmi; Bassam R Ali Journal: J Mol Neurosci Date: 2019-08-29 Impact factor: 3.444
Authors: Lindsey Welling; Jan Pieter Marchal; Peter van Hasselt; Ans T van der Ploeg; Frits A Wijburg; Jaap Jan Boelens Journal: JIMD Rep Date: 2014-09-26
Authors: Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko Journal: Mol Genet Metab Date: 2013-07-29 Impact factor: 4.797
Authors: Barbara King; Neil Marshall; Helen Beard; Sofia Hassiotis; Paul J Trim; Marten F Snel; Tina Rozaklis; Robert D Jolly; John J Hopwood; Kim M Hemsley Journal: J Inherit Metab Dis Date: 2014-11-25 Impact factor: 4.982
Authors: J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg Journal: J Inherit Metab Dis Date: 2012-09-12 Impact factor: 4.982